represents a promising treatment strategy. Furthermore, a small molecule would provide value as a molecular probe or tool compound to interrogate the cellular functions and disease implications of PTPs. Several approaches exist for the identification of small molecule inhibitors of phosphatases. While high-throughput screening of compounds in vitro has been successfully utilized to discover inhibitors of LAR, PTP1B, SHP2, CD45, and others, the technical and physical investment is considerable as is the potential for experimental artifacts leading to false negatives and positives. Alternatively, a primary screen for inhibitor scaffolds can be guided by in silico virtual screening. This purchase 168425-64-7 method involves high-throughput computational docking of small MK-1775 molecules into the crystal structure of a phosphatase active site and selecting the molecules which bind favorably, akin to a natural substrate. Following the selection of the best-scoring scaffolds, each scaffold can then be tested and validated for phosphatase inhibition in vitro. This approach has gained popularity as the number of enzymes with solved crystal structures has increased and it is advantageous in many ways. First, utilization of the phosphatase structure allows for the exclusion of molecules which have little chance of interacting with the active site, greatly reducing the number of scaffolds to be biochemically screened and improving the screen results. Second, an understanding of the unique structural features and residues comprising the active site as well as proximal folds or binding pockets can guide the selection and refinement of an inhibitor. Furthermore, an in silico approach is incredibly efficient in that it allows tens of thousands to millions of compounds to be screened virtually in a matter of weeks. The increasing number of PTP experimental structures resolved by X-ray crystallography has stimulated structure-guided efforts to identify small molecule PTP inhibitors. Drug discovery efforts focusing on PTPs are outlined in a comprehensive review written by Blaskovich, including detailed descriptions of the biological roles, target validation, screening tools and artifacts, and medicinal chemistry efforts, surrounding PTPs. As outlined in this review, molecular modeling, structure-based des
